Marcus Klarl, following 22 years in the medical device industry in Europe, has joined Titan Spine, LLC as the Vice President of Sales for Europe. For the past 12 years Klarl was involved in strategic sales, sales management, marketing, education, and clinical affairs positions in the spinal implant industry.
Marcus Klarl Joins Titan Spine

In his new position Klarl will be responsible for the sales of Titan Spine’s line of specialized Endoskeleton interbody fusion devices, which feature the company’s nano surface technology. Titan Spine officials claim that their product has been shown to promote a superior bone formation response when compared to other interbody implant materials such as polyetheretherketone (PEEK).
Prior to joining Titan Spine, Klarl developed and implemented strategic business plans for both investigational and commercially available spinal implants. He was most recently responsible for sales increases of the M6 Cervical and Lumbar Artificial Discs for Spinal Kinetics, Inc. in the German market. Prior to that, Klarl led the European sales, marketing, and clinical efforts for Impliant, Inc., the developer of the TOPS facet arthroplasty device. Klarl has also held various sales management, business development, and marketing positions with Depuy Spine, Johnson & Johnson and Steris Corporation.
“We are very fortunate to have Marcus join our team, ” said Kevin Gemas, president of Titan Spine. “His extensive experiences in the German and European spinal marketplace will be a tremendous asset to the company as we aggressively pursue additional market share for our unique devices and nano surface technology.”
Titan Spine, LLC is a surface technology company based in Mequon, Wisconsin that is focused on the design and manufacturing of proprietary interbody fusion devices for the spine.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.